TIDMYGEN

RNS Number : 7857L

Yourgene Health PLC

15 September 2021

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Share option awards

Manchester, UK - 15 September 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces an award of share options.

Award of options

The Company has today issued 1,160,000 options over Ordinary Shares of 0.1p under the Company's Enterprise Management Incentive (EMI) and unapproved share option schemes to a number of individuals in the UK and international subsidiaries.

The options are exercisable in three tranches over three financial years and are subject to certain performance conditions. The options awarded are exercisable up to 14 September 2031, at a price of 15 pence per share representing an approximation of the 30 day average share price.

Following the award of these new options, and taking into account lapsed options, the Company has 59,459,172 shares under its market-based and performance-based option schemes.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 
Yourgene Health plc                                                    Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                                investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                                   Tel: +44 (0)20 7213 0880 
Liam Murray / James Caithie / Ludovico 
 Lazzaretti 
Singer Capital Markets (Joint Corporate                                Tel: +44 (0)20 7496 3000 
 Broker) 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Stifel Nicolaus Europe Limited (Joint                                  Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
Walbrook PR Ltd (Media and Investor         Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
Paul McManus / Lianne Cawthorne                         Mob: 07980 541 893 / Mob: 07584 391 303 
 
 
 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genomic services and technologies. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. The Group's flagship in vitro diagnostic products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping.

Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger(R) Technology, the Yourgene LightBench(R) and Yourgene QS250, ideal for cell-free DNA applications in NIPT and oncology including liquid biopsy.

Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

Yourgene Health is headquartered in Manchester, UK with facilities in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". Follow us on LinkedIn and Twitter . Further information is available at www.yourgene-health.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGPUQPBUPGPGC

(END) Dow Jones Newswires

September 15, 2021 02:00 ET (06:00 GMT)

Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Yourgene Health Charts.
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Yourgene Health Charts.